Navigation Links
Contraceptive Spray Shows Positive Clinical Trial Result

The Australian drug delivery company, announced positive results from its Phase 1 clinical studies using two unique contraceptive skin sprays, each containing a progestin and an estrogen .

The first study was a Phase I, pharmacokinetic study, investigating the delivery of a formulation combining Nestorone and the synthetic estrogen, Ethinyl Estradiol. A single dose of the combination formulation was applied to the forearm of healthy volunteers.

The results showed that the dosing of the contraceptive spray provided effective delivery of both contraceptive agents, with blood concentrations of Nestorone and Ethinyl Estradiol in the target range expected to provide effective contraception. The spray was well tolerated, with no serious adverse events recorded.

This is the first time that the Acrux MDTS spray technology has effectively delivered a formulation containing a combination of two drugs, commented Acrux CEO Richard Treagus.

We are particularly pleased that our transdermal spray has been successful with Ethinyl Estradiol, as this is the active pharmaceutical compound in approximately 3 out of every 4 oral contraceptive tablets he added.

Acrux plans to proceed with a multi-dose Phase 1 study in the second half of 2007. The study will be designed to demonstrate that therapeutic blood levels of the combination contraceptive are effectively maintained with once daily dosing.

The second study was a Phase I, pharmacokinetic study, investigating the delivery of a formulation combining Nestorone and the natural estrogen, Estradiol. A single dose of the combination formulation was applied to the forearm of healthy volunteers.

The results showed that the dosing of the contraceptive spray provided effective delivery of Nestorone, with blood concentrations in the target range that is expected to provide effective contraception. The spray was well tolerated, with no serious adv erse events recorded.

Analysis of blood concentrations of Estradiol was inconclusive, due to interaction with background levels of Estradiol in the study population. Acrux has established experience with Estradiol in hormone therapy, with its lead product containing estradiol currently in pre-registration in the USA.

This, along with in-vitro results from a number of formulations containing Estradiol, gives the company confidence that it can deliver this novel combination contraceptive through the skin effectively. Acrux is planning a further Phase 1 study in the second half of 2007 in order to confirm these predictions.

Our strategy over the last 12 months has been to rapidly demonstrate the broad applicability of the Acrux spray technology across a range of contraceptive products, including combination formulations. We have made material progress in this area, which has further strengthened our commercial prospects in the global contraceptive market Richard Treagus said.

Contact:
Dr Richard Treagus, CEO & Managing Director
+61 3 8379 0100
+61 417 520 509
richard.treagus@acrux.com.au


'"/>




Related medicine news :

1. Contraceptives via Internet
2. FDA Approves Contraceptive Ring
3. Contraceptives decreases Libido
4. Contraceptives have dual effects
5. Drugs For Anthrax May Interfere With Oral Contraceptives
6. Contraceptive pill to reduce PMS
7. Smoking and Oral Contraceptives:
8. Contraceptive pills may lead to deformities in babies
9. Low-Dose Oral Contraceptives May Increase Risk For Heart Attack Or Stroke
10. Prevent Multiple Sclerosis From Oral Contraceptives
11. Usage Of Oral Contraceptives Need Not Be Feared By SLE Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... While it’s ... poses a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , ... medication in darkness or restricted lighting. As such, it eliminates the need to turn ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a ... utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the ... a CBD form that can be easily incorporated into liquid products, while reducing costs ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton ... staged a mock evacuation of the facility as part of a disaster drill on ... Echo Hose EMS and Shelton City Emergency Manager, as well as the Connecticut ...
(Date:10/13/2017)... ... 2017 , ... Ellevate Network, the leading network for professional women, brought together ... equality at their inaugural Summit in New York City in June. The event was ... of over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... 2017 , ... Talented host, actor Rob Lowe, is introducing ... new episode of "Success Files," which is an award-winning educational program broadcasted on ... subject in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... , Oct. 12, 2017 West ... in innovative solutions for injectable drug administration, today announced ... the market opens on Thursday, October 26, 2017, and ... results and business expectations at 9:00 a.m. Eastern Time. ... or 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 2017  According to the Centers for Disease Control and Prevention (CDC), ... PhysicianOne Urgent Care is helping communities across Massachusetts , ... by offering no-cost* flu shots through the end of the month. ... insurance regulations. ... get a flu shot is by the end of October, according to ...
Breaking Medicine Technology: